GH Research (GHRS) EPS (Weighted Average and Diluted) (2022 - 2025)
GH Research (GHRS) recorded quarterly EPS (Weighted Average and Diluted) of -$25035.7 in Q3 2025, up 11.06% quarter-over-quarter from -$28148.5 in Q2 2025, and down 19.87% on a YoY basis from -$31242.8 in Q3 2024.
GH Research (GHRS) EPS (Weighted Average and Diluted) (2022 - 2025) Analysis & Trends
GH Research's EPS (Weighted Average and Diluted) history runs 4 years deep, the most recent figure standing at -$25035.7 for Q3 2025.
- In Q3 2025, EPS (Weighted Average and Diluted) fell 19.87% year-over-year to -$25035.7; the TTM figure through Sep 2025 stood at -$25035.7 (down 19.87% YoY), while the FY2025 annual figure was -$0.79, down 5.33% from the prior year.
- EPS (Weighted Average and Diluted) was -$25035.7 for Q3 2025 at GH Research, up from -$28148.5 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3340.0 in Q2 2022 to a low of -$56905.3 in Q1 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$27088.7 across 4 years, with a median of -$25035.7 in 2025.
- The sharpest annual moves came in 2023 and 2025: EPS (Weighted Average and Diluted) plunged 742.8% in 2023, then advanced 5.08% in 2025.
- A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$4009.1 in 2022, then sank by 199.8% to -$12019.1 in 2023, then slumped by 73.77% to -$20886.2 in 2024, then decreased by 19.87% to -$25035.7 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$25035.7 (Q3 2025), -$28148.5 (Q2 2025), and -$56905.3 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 0.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -0.61 |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -25,035.71 |
| Jun 30, 2025 | -28,148.48 |
| Mar 31, 2025 | -56,905.26 |
| Sep 30, 2024 | -20,886.21 |
| Jun 30, 2024 | -29,654.29 |
| Mar 31, 2024 | -51,106.67 |
| Sep 30, 2023 | -12,019.15 |
| Jun 30, 2023 | -21,469.44 |
| Mar 31, 2023 | -52,080.95 |
| Sep 30, 2022 | -4,009.09 |
| Jun 30, 2022 | 3,340.00 |